Literature DB >> 2850935

Specific and non-specific serological markers in the screening for congenital CMV infection.

A el-Mekki1, L V Deverajan, S Soufi, O Strannegard, W al-Nakib.   

Abstract

IgM antibodies specific for cytomegalovirus (CMV) were demonstrated in 15 (2.6%) of 575 umbilical cord sera obtained from newborns in Kuwait. Some 93% and 50% of these CMV-IgM positive cord sera displayed markedly raised (more than normal mean +2 S.D.) content of total IgM and IgA respectively. In contrast, only 0.2 and 1.8% of the CMV-IgM negative cord sera had elevated total IgM and IgA, respectively. Rheumatoid factor (RF) was demonstrable, at concentrations of 30 IU/ml or more, in 67% of the CMV-IgM positive as compared with 3.2% of the CMV-IgM negative sera whereas interferon alpha was found in the serum of only one of these infants. These results indicate that raised total immunoglobulin, in particular IgM, concentrations and the detection of RF in cord blood are useful non-specific markers for the identification of congenital CMV infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850935      PMCID: PMC2249413          DOI: 10.1017/s0950268800029381

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  13 in total

1.  Rapid detection of human cytomegalovirus in the urine of humans.

Authors:  G Alpert; M C Mazeron; R Colimon; S Plotkin
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

2.  Congenital and perinatal cytomegalovirus infections.

Authors:  S Stagno; R F Pass; M E Dworsky; C A Alford
Journal:  Semin Perinatol       Date:  1983-01       Impact factor: 3.300

3.  Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.

Authors:  A Erice; M C Jordan; B A Chace; C Fletcher; B J Chinnock; H H Balfour
Journal:  JAMA       Date:  1987-06-12       Impact factor: 56.272

4.  Immunoglobulin M antibodies detected by enzyme-linked immunosorbent assay and radioimmunoassay in the diagnosis of cytomegalovirus infections in pregnant women and newborn infants.

Authors:  S Stagno; M K Tinker; C Elrod; D A Fuccillo; G Cloud; A J O'Beirne
Journal:  J Clin Microbiol       Date:  1985-06       Impact factor: 5.948

5.  Detection of IgM antibodies to cytomegalovirus (CMV) using an enzyme-labelled antigen (ELA).

Authors:  H Schmitz; U von Deimling; B Flehmig
Journal:  J Gen Virol       Date:  1980-09       Impact factor: 3.891

6.  Solid-phase enzyme immunoassay for determination of antibodies to cytomegalovirus.

Authors:  R V Krishna; O H Meurman; T Ziegler; U H Krech
Journal:  J Clin Microbiol       Date:  1980-07       Impact factor: 5.948

7.  Congenital cytomegalovirus infection.

Authors:  S Stagno; D W Reynolds; E S Huang; S D Thames; R J Smith; C A Alford
Journal:  N Engl J Med       Date:  1977-06-02       Impact factor: 91.245

8.  Congenital cytomegalovirus infection: diagnostic and prognostic significance of the detection of specific immunoglobulin M antibodies in cord serum.

Authors:  P D Griffiths; S Stagno; R F Pass; R J Smith; C A Alford
Journal:  Pediatrics       Date:  1982-05       Impact factor: 7.124

Review 9.  Diagnostic techniques for cytomegalovirus infection.

Authors:  P D Griffiths
Journal:  Clin Haematol       Date:  1984-10

10.  Presence of an acid-labile alpha-interferon in sera from fetuses and children with congenital rubella.

Authors:  P Lebon; F Daffos; A Checoury; L Grangeot-Keros; F Forestier; J E Toublanc
Journal:  J Clin Microbiol       Date:  1985-05       Impact factor: 5.948

View more
  2 in total

1.  The Current Status of Cytomegalovirus (CMV) Prevalence in the MENA Region: A Systematic Review.

Authors:  Hassan Al Mana; Hadi M Yassine; Nadin N Younes; Anjud Al-Mohannadi; Duaa W Al-Sadeq; Dalal Alhababi; Elham A Nasser; Gheyath K Nasrallah
Journal:  Pathogens       Date:  2019-10-31

2.  Prevalence of cytomegalovirus DNA in cord blood and voided urine obtained from pregnant women at the end of pregnancy.

Authors:  Rana Al-Awadhi; Jehad Al-Harmi; Suad Alfadhli
Journal:  Med Princ Pract       Date:  2012-10-12       Impact factor: 1.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.